Arena Pharmaceuticals Inc. (ARNA)
Symbol Info
Listed Symbol ARNA
Name Arena Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $17,970,000
Latest Fiscal EPS $-0.66
Price Info
21 Day Moving Average $47.8555
21 Day EMA $47.678860
50 Day Moving Average $51.7741
50 Day EMA $50.783460
200 Day EMA $50.421200
200 Day Moving Average 50.771430
52 Week High $64.48
52 Week Low $31.97
52 Week Change $19.060799
Alpha 0.001141
Beta 1.5297
Standard Deviation 0.147216
R2 0.127455
Periods 60
Share Information
10 Day Average Volume 387,175
20 Day Average Volume 448,298
30 Day Average Volume 419,403
50 Day Average Volume 476,325
Outstanding Shares 49,825,162
Float Shares 47,211,837
Percent Float 94.76%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 463
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 3,846,563
Institute Holdings Percent -
Institute Sold Previous 3 Months 4,779,192
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,613,325
Price Change
7 Day Price Change $1.2249985
7 Day Percent Change 2.67%
21 Day Price Change $-3.9099998
21 Day Percent Change -7.66%
30 Day Price Change $-6.119999
30 Day Percent Change -11.49%
Month To Date Price Change $1.3900
Month To Date Percent 3.04%
90 Day Price Change $-13.599998
90 Day Percent Change -22.38%
Quarter To Date $1.389999
Quarter To Date Percent 3.04%
180 Day Price Change $-1.119999
180 Day Percent Change -2.32%
200 Day Price Change $3.110001
200 Day Percent Change 7.06%
Year To Date $8.209999
Year To Date Percent 21.08%
Profile
Description Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Details
Issue Type CS
Market Cap $2,349,754,640
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 49,825,162
CEO Amit D. Munshi
Employees 194
Last Audit UE
Classification
CIK 0001080709
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 6154 Nancy Ridge Drive
San Diego, CA 92121
Website http://www.arenapharm.com
Facisimile
Telephone +1 858 453-7200
Email klind@arenapharm.com
Key Ratios
Profitability
EBIT Margin 73.50
EBITDA Margin 73.9
Pre-Tax Profit Margin -446
Profit Margin Cont 77.39
Gross Margin -
Profit Margin TOT 77.39
Income Statements
Revenue $810,727,000
Revenue Per Share $16.2714
Revenue 3 Years $16.77
Revenue 5 Years $18.66
Valuation Measures
PE Ratio 4.00
Enterprise Value $1,361,857,033
Price To Sales 2.898331
Price To Free Cash 3.600000
PE High Last 5 Years -
Price To Book 2.2
Price To Cash Flow 4.3
PE Low Last 5 Years -
Price To Tangible Book 1.9
Financial Strength
Total Debt To Equity 0.0
Int Coverage 114.2
Current Ratio 36.5
Leverage Ratio 1.1
Quick Ratio 35.8
Long Term Debt To Capital 0.04
Assets
Receivables Turnover 46.1
Invoice Turnover -
Assets Turnover 0.50
Management Effectiveness
Return Assets 61.72
Return On Equity 67.41
Return On Capital 61.88
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ARNA
Arena Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.